A human challenge study in which volunteers are deliberately infected with COVID-19 revealed much information on the progress of infection.
In a human challenge study, which is available as a pre-print, researchers from Imperial College, London, have learnt much about the progression of COVID-19 infection. Human challenge studies involve deliberately infecting individuals with an agent known to cause infection.
Such studies would not usually be undertaken during a pandemic but emerging evidence suggests that infection with COVID-19 is generally mild in healthy, young, non-smoking adults aged 18–29 years. Individuals meeting these criteria would therefore serve as low-risk participants for any type of human challenge study.
Human challenge study
With young adults without co-morbidities representing an ideal group for an infection challenge, in the present study, the UK researchers recruited 36 healthy volunteers with a mean age of 21.8 years (72% male) and no specific risk factors for severe COVID-19 infection.
As this study was undertaking during the pandemic, participants were admitted to individual negative pressure rooms in an in-patient quarantine unit with 24 hour medical monitoring and access to clinical support if required. Each were given a dose of the wild-type COVID-19 which was administered via nasal drops.
The first 10 volunteers were given pre-emptive remdesivir once two consecutive nose and throat swabs showed quantifiable COVID-19 virus after PCR testing. The rational for using the drug was to mitigate any unexpected progression of the infection to more severe disease.
Only 18 (53%) of participants developed a PCR confirmed COVID-19 infection and viral shedding from throat swabs was detectable 40 hours (roughly 1.67 days) post-inoculation and this was significantly earlier (p = 0.022) than from the nose, which was only detectable at 58 hours.
Viral particles from the throat peaked 112 hours post-inoculation (roughly 4.7 days) and after 148 hours from the nose.
In all of those who became infected, the virus could be detected at high levels for several days and remained present 14 days after inoculation.
Following inoculation, self-reported symptoms became apparent two to four days later and were generally mild-to-moderate in severity, peaking 112 hours after inoculation, which aligned with peak viral load levels.
Although anosmia developed in 9 of the infected participants, it persisted for at least 180 days in five of them. One of the interesting observations from this human challenge was how after 28 days, 33% of nose and 11% of throat samples remained positive for COVID-19.
Serum antibodies were detected among infected participants after 14 days with levels roughly doubling at day 28.
Among the 10 who were given remdesivir, six still became infected though there were no apparent differences in viral load between treated and untreated individuals.
With lateral flow antigen testing becoming a recognised strategy for home use, the researchers observed that none of the uninfected individuals tested positive, but that the median time for a positive result was 4 days post-inoculation for those who became infected and viral load was identified as a significant predictor for a positive lateral flow test result.
Summarising the findings of this human challenge study, the authors noted how only just over half of those inoculated became infected, which was something they were unable to explain, and that viral loads increased rapidly within two days of inoculation.
In addition, while symptoms were present in 89% of infected individuals, despite high viral loads, these symptoms were generally mild-to-moderate in severity. Although symptoms were present after two days these peaked between days four and five.
They added that high viral shedding occurred irrespective of symptom severity which suggested that the virus was highly transmissible.
Finally, given that viable viral was detectable 10 days after inoculation, the authors suggested that these data supported the isolation period of 10 days after symptom onset.
Citation
Chiu C et al. Safety, tolerability and viral kinetics during SARS- CoV-2 human challenge Nature portfolio 2022.
